Molecular Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
22(1), P. 284 - 294
Published: Dec. 2, 2024
Tumor
necrosis
factor-related
apoptosis-inducing
ligand
(TRAIL)
is
an
attractive
candidate
for
anticancer
therapeutics
due
to
its
efficient
pro-apoptotic
activity
against
tumor
cells
and
well-tolerated
safety
profile.
However,
the
in
vivo
antitumor
efficacy
of
TRAIL
often
limited
by
poor
targeting
capacity.
Nowadays,
B7
homologue
3
(B7-H3)
immune
checkpoint
has
emerged
as
a
promising
target
immunotherapy
drug
delivery.
Here,
we
report
achievement
tumor-targeted
delivery
genetically
fusing
it
with
B7H3-antagonistic
affibody.
The
affibody-TRAIL
fusion
protein,
named
ACT,
was
easily
expressed
Cancers,
Journal Year:
2024,
Volume and Issue:
16(3), P. 623 - 623
Published: Jan. 31, 2024
High-grade
gliomas
(HGG)
account
for
approximately
10%
of
central
nervous
system
(CNS)
tumors
in
children
and
25%
CNS
adults.
Despite
their
rare
occurrence,
HGG
are
a
significant
clinical
problem.
The
standard
therapeutic
procedure
both
pediatric
adult
patients
with
is
the
surgical
resection
tumor
combined
chemotherapy
radiotherapy.
intensive
treatment,
5-year
overall
survival
below
20–30%.
This
rate
even
lower
most
common
adults
(glioblastoma),
at
less
than
5%.
It
is,
therefore,
essential
to
search
new
methods
that
can
extend
rate.
One
options
use
immune
cells
(T
lymphocytes/natural
killer
(NK)
cells)
expressing
chimeric
antigen
receptor
(CAR).
objective
following
review
present
latest
results
preclinical
studies
evaluating
efficacy
CAR-T
CAR-NK
therapy.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(15), P. 11903 - 11903
Published: July 25, 2023
To
achieve
the
scheme
of
"magic
bullets"
in
antitumor
therapy,
antibody-drug
conjugates
(ADCs)
were
developed.
ADCs
consist
antibodies
targeting
tumor-specific
antigens,
chemical
linkers,
and
cytotoxic
payloads
that
powerfully
kill
cancer
cells.
With
approval
ado-trastuzumab
emtansine
(T-DM1)
fam-trastuzumab
deruxtecan
(T-DXd),
therapeutic
potentials
breast
have
come
into
spotlight.
Nearly
30
for
are
under
exploration
to
move
targeted
therapy
forward.
In
this
review,
we
summarize
presenting
emerging
agents
targets
ADCs.
The
ADC
structure
development
history
also
concluded.
Moreover,
challenges
faced
prospected
future
directions
field
reviewed,
which
give
insights
novel
treatments
with
cancer.
Cancer Research Communications,
Journal Year:
2024,
Volume and Issue:
4(5), P. 1369 - 1379
Published: May 6, 2024
B7-H3
(CD276)
is
a
transmembrane
glycoprotein
of
the
B7
immune
checkpoint
superfamily
that
has
emerged
as
promising
therapeutic
target.
To
better
understand
applicability
B7-H3-directed
therapies,
we
analyzed
156,791
samples
comprising
50
cancer
types
to
interrogate
clinical,
genomic,
transcriptomic,
and
immunologic
correlates
mRNA
expression.
DNA
(592-gene/whole-exome)
RNA
(whole-transcriptome)
sequencing
was
performed
from
submitted
Caris
Life
Sciences.
high
versus
low
expression
based
on
top
bottom
quartiles
for
each
type.
Patients'
overall
survival
determined
insurance
claims
data.
Pathway
analysis
using
gene
set
enrichment
analyses.
Immune
cell
fractions
were
inferred
quanTIseq.
expressed
across
several
human
malignancies
including
prostate,
pancreatic,
ovarian,
lung
cancers.
High
associated
with
differences
in
survival,
possibly
indicating
prognostic
role
some
When
examining
molecular
features
all
types,
did
not
identify
recurrent
associations
between
genetic
alterations
TP53,
RB1,
KRAS.
However,
find
consistent
epithelial-to-mesenchymal
transition,
Wnt,
TGFβ,
Notch
signaling
pathways.
In
addition,
tumors
are
greater
proportions
M1
macrophages,
but
lower
CD8+
T
cells.
We
have
begun
define
types.
report
novel
clinical
B7-H3-high
which
may
inform
how
current
therapeutics
should
be
deployed
prioritized.
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Feb. 16, 2024
Disulfidptosis
is
a
condition
where
dysregulated
NAPDH
levels
and
abnormal
accumulation
of
cystine
other
disulfides
occur
in
cells
with
high
SLC7A11
expression
under
glucose
deficiency.
This
disrupts
normal
formation
disulfide
bonds
among
cytoskeletal
proteins,
leading
to
histone
skeleton
collapse
triggering
cellular
apoptosis.
However,
the
correlation
between
disulfidptosis
immune
responses
relation
glioblastoma
survival
rates
immunotherapy
sensitivity
remains
understudied.
Therefore,
we
utilized
The
Cancer
Genome
Atlas
Chinese
Glioma
identify
disulfidptosis-related
checkpoint
genes
established
an
overall
(OS)
prediction
model
comprising
six
genes:
CD276,
TNFRSF
14,
TNFSF14,
TNFSF4,
CD40,
TNFRSF18,
which
could
also
be
used
for
predicting
sensitivity.
We
identified
cohort
patients
classified
as
high-risk,
exhibited
upregulation
angiogenesis,
extracellular
matrix
remodeling,
epithelial-mesenchymal
transition
well
immunosuppressive
tumor
microenvironment
(TME)
enriched
associated
macrophages,
neutrophils,
CD8
+
T-cell
exhaustion.
Immunohistochemical
staining
CD276
144
cases
further
validated
its
negative
OS
glioma.
has
potential
induce
chronic
inflammation
TME
glioblastoma.
Translational Cancer Research,
Journal Year:
2024,
Volume and Issue:
13(2), P. 833 - 846
Published: Feb. 1, 2024
B7-H3
(CD276)
is
overexpressed
in
diverse
malignant
tumors
and
plays
critical
roles
tumorigenesis
metastasis.
However,
the
mechanism
of
lung
cancer
remains
unclear.
This
study
aimed
to
explore
interaction
between
α-enolase
(ENO1)
progression.
Brain Sciences,
Journal Year:
2025,
Volume and Issue:
15(2), P. 212 - 212
Published: Feb. 19, 2025
Isocitrate
dehydrogenase
(IDH)
wild-type
(wt)
glioblastoma
is
an
aggressive
malignancy
associated
with
poor
clinical
outcomes,
marked
by
high
heterogeneity
and
resistance
to
treatment.
This
study
aims
investigate
the
prognostic
significance
of
B7-H3
expression
in
IDH
wt
its
potential
association
including
overall
survival
(OS)
progression-free
(PFS).
Additionally,
relationship
between
PD-L1
was
explored.
A
retrospective
cohort
86
patients,
all
whom
underwent
surgery,
radiotherapy,
temozolomide
treatment,
analyzed.
quantified
using
immunoreactivity
score
(IRS),
classifying
samples
as
low
(IRS
≤
4)
or
>
4).
evaluated
based
on
tumor
immune
cell
staining,
>5%
positivity
indicating
significant
expression.
High
significantly
poorer
OS
PFS.
Co-expression
prevalent,
particularly
among
younger
male
patients
unifocal
tumors;
however,
did
not
show
a
correlation
outcomes.
appears
be
promising
biomarker
may
serve
target
for
developing
combination
therapies,
integrating
B7-H3-targeting
treatments
checkpoint
inhibitors.
Further
prospective
studies
are
necessary
validate
these
findings
explore
therapeutic
strategies.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: March 22, 2025
Reproductive
disorders
in
dairy
cows
represent
a
significant
challenge
to
the
advancement
of
industry.
Pregnancy
success
is
closely
related
mechanism
immune
tolerance,
with
PD-1/PD-L1
signaling
pathway
playing
role
regulation,
which
associated
tolerance
and
pregnancy
maintenance.
MicroRNAs
can
regulate
pivotal
molecules
within
pathway,
physiological
activities,
disease
processes.
p65
PD-L1
expression
was
significantly
increased
early
pregnant
uterine
epithelium.
In
contrast,
homogeneous
endometrial
epithelium
E2
P4
co-stimulated
bEECs
changed
stimulation
time
concentration.
MiR-155
reduced
identified
as
molecular
target
miR-155
using
dual
luciferase
assay
mimics/inhibitor
transfection,
inhibited
by
binding
3'-UTR
mRNA.
The
regulation
confirmed
through
knockdown
si-p65
overexpression
pcDNA3.1-p65.
context
pregnancy,
observed
p65,
thereby
regulating
at
